tiprankstipranks
Titan Pharmaceuticals (DE:TN7)
BERLIN:TN7

Titan Pharmaceuticals (TN7) Stock Price & Analysis

0 Followers

TN7 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€4.40 - €19.03
Previous Close€7.48
Volume0.00
Average Volume (3M)94.00
Market Cap
€6.06M
Enterprise Value-€1.25M
Total Cash (Recent Filing)$8.10M
Total Debt (Recent Filing)$97.00K
Price to Earnings (P/E)N/A
Beta0.15
Nov 11, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,016,295
10 Day Avg. Volume0
30 Day Avg. Volume94
Standard Deviation0.16
R-Squared0.08
Alpha-0.00583
Financial Highlights & Ratios
Price to Book (P/B)0.50
Price to Sales (P/S)127.79
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.11
Enterprise Value/Gross Profit-2.25
Enterprise Value/Ebitda0.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

TN7 FAQ

What was Titan Pharmaceuticals’s price range in the past 12 months?
Titan Pharmaceuticals lowest stock price was €4.40 and its highest was €19.03 in the past 12 months.
    What is Titan Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Titan Pharmaceuticals’s upcoming earnings report date?
    Titan Pharmaceuticals’s upcoming earnings report date is Nov 11, 2024 which is in 227 days.
      How were Titan Pharmaceuticals’s earnings last quarter?
      Titan Pharmaceuticals released its earnings results on Nov 13, 2023. The company reported -€0.02 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.02.
        Is Titan Pharmaceuticals overvalued?
        According to Wall Street analysts Titan Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Titan Pharmaceuticals pay dividends?
          Titan Pharmaceuticals does not currently pay dividends.
          What is Titan Pharmaceuticals’s EPS estimate?
          Titan Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Titan Pharmaceuticals have?
          Currently, no data Available
          What happened to Titan Pharmaceuticals’s price movement after its last earnings report?
          Titan Pharmaceuticals reported an EPS of -€0.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.152%.
            Which hedge fund is a major shareholder of Titan Pharmaceuticals?
            Currently, no hedge funds are holding shares in DE:TN7
            ---

            Titan Pharmaceuticals Stock Smart Score

            N/A
            Not Ranked
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Technicals

            SMA
            Negative
            20 days / 200 days
            Momentum
            -61.99%
            12-Months-Change

            Fundamentals

            Return on Equity
            -105.55%
            Trailing 12-Months
            Asset Growth
            59.32%
            Trailing 12-Months

            Company Description

            Titan Pharmaceuticals

            Titan Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in development of therapeutics for the treatment of medical disorders. Its products include Probuphine, Ropinirole Implant, and T3 Implant. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.
            ---

            TN7 Stock 12 Months Forecast

            Average Price Target

            {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"€26","-1":"-€1","5.75":"€5.75","12.5":"€12.5","19.25":"€19.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,5.75,12.5,19.25,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2022","6":"Sep<br/>2022","9":"Dec<br/>2022","12":"Feb<br/>2023","25":"Feb<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.536,16.187076923076923,14.838153846153848,13.489230769230769,12.140307692307694,10.791384615384615,9.442461538461538,8.093538461538461,6.7446153846153845,5.395692307692308,4.046769230769231,2.697846153846154,1.3489230769230751,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.536,16.187076923076923,14.838153846153848,13.489230769230769,12.140307692307694,10.791384615384615,9.442461538461538,8.093538461538461,6.7446153846153845,5.395692307692308,4.046769230769231,2.697846153846154,1.3489230769230751,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.536,16.187076923076923,14.838153846153848,13.489230769230769,12.140307692307694,10.791384615384615,9.442461538461538,8.093538461538461,6.7446153846153845,5.395692307692308,4.046769230769231,2.697846153846154,1.3489230769230751,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.992,"date":1646092800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.068,"date":1648771200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.087,"date":1651363200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.848,"date":1654041600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.296,"date":1656633600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.41,"date":1659312000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.039,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.259,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.179,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.864,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.415,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.552,"date":1672963200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.536,"date":1675382400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
            Similar Stocks
            Company
            Price & Change
            Follow
            Titan Pharmaceuticals
            Palatin Technologies
            Acasti Pharma
            Onconova Therapeutics
            Akari Therapeutics
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis